Association of TP53 P72R and MDM2 SNP309 variants with susceptibil-ity to chronic myeloid leukaemia development in Algerian population: TP53 P72R C allele is a strong risk marker and MDM2 SNP309 G allele has a protective effect


  • Khedidja Benseddik
  • Rym Abderrahmane
  • Abdellah Boudjemaa
  • Aberkane Meriem
  • Dorgham Samia
  • Touala Chaîla Zohra
  • Meroufel Djabaria Naima



Chronic myeloid leukaemia is a monoclonal myeloproliferative syndrome, whose development is related to disturbance of growth, survival, and apop-totic pathways, such as MDM2-p53 pathway, mainly due to the abnormal kinase activity of BCR-ABL. A lot of work has to be done to understand chron-ic myeloid leukaemia genetic predisposition. This is a pilot study that search-es for association between TP53 P72R variant (rs1042522); and MDM2 T309G variant (rs2279744), and the risk of chronic myeloid leukaemia occur-rence in the Algerian population. It is a case-control study using DNA sam-ples of 74 Algerian chronic myeloid leukaemia patients and 104 healthy con-trol individuals. Our results attested that TP53 P72R C allele (Pro) was strong-ly associated with increased risk of chronic myeloid leukaemia, and that TP53 P72R homozygous CC genotype should be a genetic susceptibility factor in the pathogenesis of chronic myeloid leukaemia independently of age and of gender. Furthermore, MDM2 SNP309 TT genotype was moderately associat-ed with a risk of chronic myeloid leukaemia occurrence. In conclusion, our data suggest that, in Algerian population, TP53 P72R C allele (Pro) could be a possible biomarker of chronic myeloid leukaemia susceptibility, and that MDM2 SNP309 TT genotype seems to be a low penetrance risk factor of chronic myeloid leukaemia susceptibility.






Research Articles